Ranbaxy Laboratories, Inc.

Daiichi Sankyo Company, Limited

Ashwani Kumar Verma

Rie Miyauchi

Masatoshi Nagamochi

Shin Iimura

Sunanda Ghosh Dastidar

Abhijit Ray

Masayuki Ishizaki

Ashok Rattan

Punit Kumar Srivastava

Kumaragurubaran Nagaswamy

Pradip Balu Wagh

Sonali Nanasaheb Pansare

Pramod Raosaheb Markad

Lalima Sharma

Yogesh Balasaheb Khairnar

Soma Ghosh

Takeshi Murata

Balkrishna Ramchandra Kale

Aniruddha Mondal

Sanjay Malhotra

Rijwan Jaffer Momin

Sudershan Kumar Arora

Jitendra Anant Sattigeri

Rita Katoch

Sankaranarayanan Dharmarajan

Sagar Ramdas Amale

Jasbir Singh Arora

Mohammed Salman

Yogesh Baban Surase

Suresh Kumar Gorla

Priyanka Patel

Kirandeep Kaur Samby

Rajkumar Shirumalla

Shirumalla Raj Kumar

The present invention relates to a pyrazole derivative of formula (I), a pharmaceutically acceptable salt thereof, a prodrug thereof, a hydrate thereof, stereoisomer thereof or a deuterium form thereof, wherein, n, Y, R, R, R, R, R, Rand Rare as defined hereinafter in the specification, a pharmaceutical composition comprising a compound of formula (I) as an active ingredient, methods of production, and methods of use thereof.  Particularly, the present invention provides a compound of formula (I) as inhibitors of phosphatidylinositol-3-kinase (PI3K), which can be used for treating or preventing inflammatory, autoimmune, orphan and hyperproliferative disease and disorder.

6-morpholinyl-2-pyrazolyl-9H-purine derivatives and their use as PI3K inhibitors

The present invention provides a heterocyclic compound of formula (I), a pharmaceutically acceptable salt thereof, a prodrug thereof or a hydrate thereof, wherein A, A' B, D, R, Rand Rare as defined herein, a pharmaceutical composition comprising a compound of formula (I) as an active ingredient, methods of production, and methods of use thereof. Particularly, the present invention provides a compound of formula (I) useful for treating or preventing a disease, condition or disorder associated with protein kinases, preferably Janus Kinase family.

Heterocyclic compounds as protein kinase inhibitors

The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds disclosed herein can be useful for inhibition and prevention of inflammation and associated pathologies including inflammatory and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection, psoriasis, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, cancer, pruritis and allergic rhinitis. Pharmacological compositions containing compounds disclosed herein and the methods of treating bronchial asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, multiple sclerosis, type I diabetes, psoriasis, allograft rejection, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, cancer, pruritis, allergic rhinitis and other inflammatory and/or autoimmune disorders, using the compounds are also provided.

Monosaccharide derivatives

The present invention relates to 5-lipoxygenase inhibitors. Compounds disclosed herein can be useful in the treatment of bronchial asthma, chronic obstructive pulmonary disorder, arthritis, type I diabetes, multiple sclerosis, allograft rejection, psoriasis, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, cancer, pruritis, urticaria, atopic dermatitis, allergic rhinitis, other inflammatory, and autoimmune diseases. Processes for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds and their use as 5-lipoxygenase inhibitors are also provided.

5-lipoxygenase inhibitors

The present invention relates to the derivatives of specially substituted azole compounds which have improved antifungal activity as compared with presently available agents in this class and the processes for the preparation thereof. This invention also relates to pharmaceutical preparations containing the compounds of the present invention and their use in treating and/or preventing the fungal infections in mammals, preferably humans.

Azole compounds as anti-fungal agents

The present invention relates to the derivatives of specially substituted azole compounds which have improved antifungal activity as compared to known compounds such as fluconazole and itraconazole and the processes for the preparation thereof. This invention also relates to pharmaceutical compositions containing the compounds of the present invention and their use in treating and/or preventing fungal infections in mammals, preferably humans.

Azole compounds as therapeutic agents for fungal infections

Growing community of inventors

New Delhi, India

Ashwani Kumar Verma